The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice
- PMID: 6161889
- PMCID: PMC1458088
The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice
Abstract
The possibility of enhancing the antigenicity of tumour cells by chemically attaching purified protein derivative (PPD) of tubercle bacillus as an immunogenic carrier determinant into the tumour cell surface has been explored in these studies. It was observed that multiple immunizations with PPD-coupled tumour cells did potentiate a marked anti-rumour response even to tumours that were very weakly antigenic. Moreover, such immunizations could be used to retard the growth of tumours in previously unimmunized animals. An attempt has been made to elucidate the important factors involved when PPD heterogenized tumour cells are used for immunization.
Similar articles
-
The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand.Immunology. 1981 Feb;42(2):329-36. Immunology. 1981. PMID: 6161888 Free PMC article.
-
Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells.Immunology. 1984 Apr;51(4):755-63. Immunology. 1984. PMID: 6200428 Free PMC article.
-
Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice.Nature. 1978 Feb 2;271(5644):463-4. doi: 10.1038/271463a0. Nature. 1978. PMID: 342968 No abstract available.
-
Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity?Immunol Today. 1991 Oct;12(10):352-5. doi: 10.1016/0167-5699(91)90065-2. Immunol Today. 1991. PMID: 1720318 Review.
-
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals.Ciba Found Symp. 1986;119:25-57. doi: 10.1002/9780470513286.ch3. Ciba Found Symp. 1986. PMID: 3015516 Review.
Cited by
-
Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.Immunology. 1984 Dec;53(4):601-10. Immunology. 1984. PMID: 6209204 Free PMC article.
-
A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung.Br J Cancer. 1985 Mar;51(3):415-7. doi: 10.1038/bjc.1985.56. Br J Cancer. 1985. PMID: 3882114 Free PMC article. Clinical Trial. No abstract available.
-
Tumour immunology: a review.J R Soc Med. 1984 Dec;77(12):1023-9. doi: 10.1177/014107688407701207. J R Soc Med. 1984. PMID: 6439868 Free PMC article. Review. No abstract available.
-
The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand.Immunology. 1981 Feb;42(2):329-36. Immunology. 1981. PMID: 6161888 Free PMC article.
-
Purified protein derivative (PPD).Springer Semin Immunopathol. 1988;10(4):301-4. doi: 10.1007/BF02053842. Springer Semin Immunopathol. 1988. PMID: 3146815 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources